Jul 15, 2010
9:00 AM ET
|
 |
Listen to webcast.
Note: These videos were shown at the meeting but not webcast.
You may view them here at any time.
|
 |
VelociGene® and VelocImmune® Technologies: A Brief History |
|
Process Development and Manufacturing |
 |
Introduction: Leonard Schleifer, M.D., Ph.D., Chief Executive Officer 3.3 MB
|
| |
R&D Overview: George Yancopoulos, M.D., Ph.D., Chief Scientific Officer 8.8 MB
|
| |
Early Clinical Development: Neil Stahl, Ph.D., Senior Vice President, Research and Development Sciences 1.8 MB
|
| |
Early Stage Development: Peter Powchik, M.D., Senior Vice President, Clinical Development 1.7 MB
|
| |
Oncology: Alain Thibault, M.D., Vice President, Clinical Sciences, Oncology 1.1 MB
|
| |
VEGF Trap–Eye: Robert Vitti, M.D., Executive Director, Clinical Sciences, Ophthalmology 8.7 MB
|
| |
ARCALYST® (rilonacept): Bob Terifay, Senior Vice President, Commercial 2.3 MB
|
| |
Financial Overview: Murray Goldberg, Chief Financial Officer 929.3 KB
|
| |
Industrial Operations and Product Supply: Dan Van Plew, Senior Vice President, Industrial Operations and Product Supply 5.5 MB
|
| |
Conclusion: Leonard Schleifer, M.D., Ph.D., Chief Executive Officer
2.1 MB
|
|
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds